Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Oncocyte, Qiagen, Myriad Genetics, Iaso Biotherapeutics

NEW YORK – Oncocyte this week said it has signed an agreement with Qiagen to support the launch of sotorasib (Amgen's Lumakras) through Qiagen's "Day One" lab readiness program, which is designed to expedite patient access to Qiagen's companion diagnostic tests following regulatory approval of the tests and associated drugs. Last week, sotorasib received US Food and Drug Administration approval for previously treated, locally advanced, or metastatic non-small cell lung cancer patients whose tumors harbor a KRAS G12C mutation. It was approved alongside Qiagen's Therascreen KRAS RGQ PCR kit, a tissue-based companion diagnostic, and Qiagen selected Oncocyte as a "Day One" lab that will offer the assay. Oncocyte noted that the Qiagen tissue test complements its own DetermaRx assay for early-stage NSCLC patients, as well as its DetermaTx and DetermaIO tests for later-stage patients, which the company plans to launch in the second half of this year.

Myriad Genetics this week said it has completed the sale of its myPath melanoma test and the lab in which the test is performed to Castle Biosciences. Utah-based Myriad announced in April that it planned sell these assets to Castle for $32.5 million in cash as part of a broader restructuring plan. The sale was finalized on May 28.

Iaso Biotherapeutics said this week that the China National Medical Products Administration has approved an investigational new drug application for CT120, Iaso's dual targeting CAR T-cell therapy for patients with relapsed, refractory B-cell acute lymphoblastic leukemia. The autologous treatment, designed to target both CD19 and CD22, is Iaso's second investigational cell therapy to enter clinical-stage development; the company is also developing CT103A, a BCMA-targeted CAR T-cell therapy, for multiple myeloma and autoimmune diseases.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared in Precision Oncology News.